Related Experiment Videos
Short-term sleep laboratory evaluation of midazolam in chronic insomniacs. Preliminary results
Abstract:
The effects of 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a] [1,4]benzodiazepine (midazolam, Ro 21-3981, Dormicum) in oral formulation of 15 and 30 mg on the sleep cycle of patients suffering from insomnia were assessed by means of polysomnographic recordings using a double-blind cross-over design. Both doses of midazolam were effective in improving sleep on short-term administration. In addition, significantly larger decrements of non-REM (NREM) sleep latency and of wake time through the 3rd third of night and nonsignificant trends toward smaller number of awakenings as well as shorter total wake time and longer NREM sleep time were induced by the 30 mg dose. Irrespective of the dosage sleep was almost exclusively increased at the expense of NREM sleep. Following 3 days treatment there was no rebound insomnia. These preliminary results suggest that the 15 mg dose could be appropriate in patients with difficulties in falling asleep, while the 30 mg dose would be more appropriate for patients who also experience difficulties in staying asleep.
Insights
Midazolam (Dormicum) effectively improved sleep in insomnia patients short-term. Higher 30mg doses reduced sleep latency and nighttime awakenings more significantly without rebound insomnia.
Area of Science:
- Pharmacology
- Sleep Medicine
- Clinical Trials
Background:
- Insomnia is a prevalent sleep disorder affecting millions worldwide.
- Benzodiazepines are commonly prescribed for insomnia, but their effects on sleep architecture require detailed investigation.
- Midazolam, an oral benzodiazepine, has shown hypnotic properties.
Purpose of the Study:
- To evaluate the effects of oral midazolam (15 mg and 30 mg) on the sleep cycle of patients with insomnia.
- To determine the efficacy and safety of short-term midazolam administration for insomnia.
- To compare the impact of different midazolam dosages on sleep parameters.
Main Methods:
- A double-blind, cross-over study design was employed.
- Polysomnographic recordings were used to objectively measure sleep parameters.
- Patients with insomnia received oral formulations of midazolam at 15 mg and 30 mg doses.
Main Results:
- Both 15 mg and 30 mg doses of midazolam demonstrated short-term efficacy in improving sleep.
- The 30 mg dose significantly reduced non-REM (NREM) sleep latency and wake time in the latter part of the night.
- Sleep was primarily increased by reducing NREM sleep, with no rebound insomnia observed after 3 days of treatment.
Conclusions:
- Oral midazolam is effective for short-term treatment of insomnia.
- The 15 mg dose may be suitable for patients with sleep onset difficulties.
- The 30 mg dose appears more beneficial for patients experiencing both sleep onset and sleep maintenance issues.